Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C24H47NO7
CAS Number:
Molecular Weight:
461.63
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 25 mg (860535P-25mg), pkg of 1 × 5 mg (860535P-5mg), pkg of 1 × 50 mg (860535P-50mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@](N)([H])CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O
InChI
1S/C24H47NO7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(27)18(25)17-31-24-23(30)22(29)21(28)20(16-26)32-24/h14-15,18-24,26-30H,2-13,16-17,25H2,1H3/b15-14+/t18?,19-,20-,21-,22+,23+,24-/m1/s1
InChI key
HHJTWTPUPVQKNA-SKXACSAKSA-N
General description
Glucosyl sphingosine is a lyso derivative of glucosylceramide (GlcCer).
Application
Glucosyl(β) Sphingosine (d18:1) or D-glucosyl-β1-1′-D-erythro-sphingosine may be used:
- to screen lipids that rapidly and reversibly alter transepithelial electrical resistance (TER) or tight junction (TJ) permeability in epithelial tissue
- as a standard for the quantification of glucosyl sphingosine in Gaucher patients using liquid chromatography electrospray ionization tandem mass spectrometric (LC/ESI-MS/MS)
- as an internal standard for the quantification of lysoglucosylceramide in plasma for Gaucher disease using liquid chromatography with tandem mass spectrometry (LC-MS/MS)
Biochem/physiol Actions
Glucosyl sphingosine is a potential biomarker for Gaucher′s disease. It modulates Ca2+ release in the brain microsomes.
Packaging
5 mL Amber Glass Screw Cap Vial (860535P-25mg)
5 mL Amber Glass Screw Cap Vial (860535P-50mg)
5 mL Amber Glass Screw Cap Vial (860535P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Arndt Rolfs et al.
PloS one, 8(11), e79732-e79732 (2013-11-28)
Gaucher disease (GD) is the most common lysosomal storage disorder (LSD). Based on a deficient β-glucocerebrosidase it leads to an accumulation of glucosylceramide. Standard diagnostic procedures include measurement of enzyme activity, genetic testing as well as analysis of chitotriosidase and
Emyr Lloyd-Evans et al.
The Journal of biological chemistry, 278(26), 23594-23599 (2003-04-24)
We recently demonstrated that elevation of intracellular glucosylceramide (GlcCer) levels results in increased functional Ca2+ stores in cultured neurons, and suggested that this may be due to modulation of ryanodine receptors (RyaRs) by GlcCer (Korkotian, E., Schwarz, A., Pelled, D.
Nick Dekker et al.
Blood, 118(16), e118-e127 (2011-08-27)
Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, leads to prominent glucosylceramide accumulation in lysosomes of tissue macrophages (Gaucher cells). Here we show glucosylsphingosine, the deacylated form of glucosylceramide, to be markedly increased in plasma of symptomatic